8-K: 60 Degrees Pharma Grants Right of Reference for Malaria Drug to University of Kentucky

60 Degrees Pharmaceuticals has granted the University of Kentucky a right of reference to its malaria drug ARAKODA's new drug application to support the university's Phase IIb study of SJ733.

Summary

• 60 Degrees Pharmaceuticals has granted the University of Kentucky a right of reference to its New Drug Application (NDA) for ARAKODA (tafenoquine).
• This right of reference allows the FDA to review 60 Degrees Pharma's regulatory file when evaluating new study protocols for the University of Kentucky's SJ733 Phase IIb program.
• The University of Kentucky is conducting a Phase IIb clinical study of SJ733, an oral ATP4 inhibitor, in combination with tafenoquine for the treatment of vivax malaria.
• The study aims to evaluate the safety, tolerability, and pharmacokinetics of a single-dose combination of SJ733 and tafenoquine.
• The current standard treatment for vivax malaria involves a combination of tafenoquine and chloroquine over three days, but resistance to chloroquine is a growing concern.
• The study is funded by the Global Health Innovative Technology Fund.
• 60 Degrees Pharma will supply tafenoquine and placebos for the trial.
• The study is targeting data that supports a 1 to 3 dose combination of SJ733 and tafenoquine for the radical cure of P. vivax malaria.
• The study will set the stage for subsequent pivotal Phase 3 studies.

Sentiment

Score: 6

Explanation: The news is positive in terms of drug development progress, but the company's financial risks and going concern issues temper the overall sentiment.

Positives

• The collaboration with the University of Kentucky and Eisai Co. Ltd. could lead to a more effective treatment for vivax malaria.
• The right of reference granted to the University of Kentucky will streamline the FDA review process for the SJ733 Phase IIb program.
• The study is targeting a single-dose combination of SJ733 and tafenoquine, which could improve patient compliance.
• The study is funded by the Global Health Innovative Technology Fund, reducing the financial burden on 60 Degrees Pharma.
• The use of ARAKODA, an already FDA-approved drug, in the study could accelerate the development process.

Negatives

• The press release includes a cautionary note regarding forward-looking statements, indicating potential risks and uncertainties.
• The company has no manufacturing capacity, which could lead to delays in bringing products to market.
• The company's ability to continue as a going concern is in doubt.
• The company may not be eligible for Australian government research and development tax rebates.

Risks

• There is substantial doubt about the company's ability to continue as a going concern.
• The company may not be able to obtain FDA approval for non-malaria indications for tafenoquine or Celgosivir.
• Clinical trials may not be successful, or patient recruitment may be slow.
• The company has no manufacturing capacity, which could lead to delays.
• The company may not be eligible for Australian government research and development tax rebates.

Future Outlook

The company is focused on developing new medicines for infectious diseases and is working with the University of Kentucky to advance the development of a new treatment for vivax malaria. The company is also exploring non-malaria indications for tafenoquine.

Management Comments

• Dr. R. Kip Guy, principal investigator on the Phase IIb study, stated that the study has the potential to pave the way for very meaningful improvement in malaria treatment around the world.

Industry Context

The development of new treatments for malaria is crucial due to increasing resistance to existing drugs. This collaboration between 60 Degrees Pharma, the University of Kentucky, and Eisai Co. Ltd. addresses the need for innovative solutions in the fight against malaria, particularly vivax malaria, which affects millions globally.

Comparison to Industry Standards

• The current standard treatment for vivax malaria involves a combination of tafenoquine and chloroquine administered over three days, but resistance to chloroquine is a growing concern, making the development of new treatments like the SJ733-tafenoquine combination critical.
• Other companies such as GlaxoSmithKline (GSK) and Novartis are also involved in malaria drug development, but the specific approach of combining SJ733 with tafenoquine is unique to this collaboration.
• The Phase IIb study is a critical step in the drug development process, and its success will determine whether the SJ733-tafenoquine combination will move to Phase 3 trials and potentially become a new treatment option.

Stakeholder Impact

• Shareholders may view this collaboration positively as it could lead to new revenue streams.
• Patients with vivax malaria could benefit from a new, potentially more effective treatment.
• The University of Kentucky and Eisai Co. Ltd. will benefit from the collaboration and the potential for a successful drug development.

Next Steps

• The University of Kentucky will commence a Phase IIb clinical study of SJ733 combined with tafenoquine.
• Eisai will manage the manufacture of a new batch of SJ733 clinical trial material.
• The University of Kentucky will oversee the regulatory filings to amend the current US-FDA IND for development of SJ733.

Key Dates

Keywords

malaria, tafenoquine, ARAKODA, SJ733, clinical trial, FDA, Phase IIb, vivax malaria, infectious diseases, pharmaceuticals